Pre-exposure prophylaxis adherence and discontinuation at an urban pre-exposure prophylaxis program in Atlanta, Georgia

被引:0
作者
Yacout, Hiba [1 ,4 ]
Smith, Bradley L. [1 ]
Foster, Shelbie [1 ]
Lora, Meredith [1 ,2 ]
Niles-Carnes, Larisa V. [1 ]
Zheng, Ziduo [3 ]
Kundu, Suprateek [3 ]
Cantos, Valeria D. [2 ]
机构
[1] Grady Hlth Syst, Dept Pharm, Atlanta, GA USA
[2] Emory Univ, Sch Med, Atlanta, GA USA
[3] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA USA
[4] Grady Hlth Syst, 80 Jesse Hill Jr Dr SE, POB 26041, Atlanta, GA 30303 USA
来源
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | 2023年 / 6卷 / 06期
关键词
HIV; medication adherence; medication discontinuation; preexposure prophylaxis (PrEP); HIV PREVENTION; MEN; SEX; SAFETY; WOMEN; PREP;
D O I
10.1002/jac5.1792
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oral pre-exposure prophylaxis (PrEP) effectiveness is directly correlated with medication adherence. Grady Health System (GHS) developed a PrEP program to optimize PrEP uptake in Atlanta, Georgia. The purpose of this study is to determine PrEP medication adherence and its associated factors during the first 18 months of the program's implementation. A single-center, retrospective chart review was conducted on patients enrolled in a PrEP program in Atlanta, Georgia, between June 1, 2018 and February 29, 2020, who received more than one PrEP prescription. The primary outcome was mean adherence to PrEP, using the medication possession ratio (MPR). This study included 154 primarily young patients (mean 34 years of age), Black (70.8%), uninsured (59.1%), and cisgender men (62.3%). Mean PrEP adherence was 89.2%; 77.3% of patients had an MPR >= 80% (high adherence). Of all patients, 71 (46%) met PrEP discontinuation criteria. This PrEP program demonstrated high levels of PrEP adherence with discontinuation rates similar to other PrEP programs nationwide, despite a higher index of social vulnerability in the area. Future areas of research include identifying the specific program-related factors that may optimize PrEP adherence in areas with high indices of social vulnerability.
引用
收藏
页码:576 / 580
页数:5
相关论文
共 28 条
[1]   Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial: Concordance With Drug Detection [J].
Amico, K. Rivet ;
Marcus, Julia L. ;
McMahan, Vanessa ;
Liu, Albert ;
Koester, Kimberly A. ;
Goicochea, Pedro ;
Anderson, Peter L. ;
Glidden, David ;
Guanira, Juan ;
Grant, Robert .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 66 (05) :530-537
[2]   Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men [J].
Anderson, Peter L. ;
Glidden, David V. ;
Liu, Albert ;
Buchbinder, Susan ;
Lama, Javier R. ;
Vicente Guanira, Juan ;
McMahan, Vanessa ;
Bushman, Lane R. ;
Casapia, Martin ;
Montoya-Herrera, Orlando ;
Veloso, Valdilea G. ;
Mayer, Kenneth H. ;
Chariyalertsak, Suwat ;
Schechter, Mauro ;
Bekker, Linda-Gail ;
Kallas, Esper Georges ;
Grant, Robert M. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (151)
[3]  
[Anonymous], 2018, CDC's Social Vulnerability Index
[4]  
[Anonymous], PREEXPOSURE PROPHYLA
[5]  
Atlanta, AIDSVU PUBLISHED DEC
[6]   Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women [J].
Baeten, J. M. ;
Donnell, D. ;
Ndase, P. ;
Mugo, N. R. ;
Campbell, J. D. ;
Wangisi, J. ;
Tappero, J. W. ;
Bukusi, E. A. ;
Cohen, C. R. ;
Katabira, E. ;
Ronald, A. ;
Tumwesigye, E. ;
Were, E. ;
Fife, K. H. ;
Kiarie, J. ;
Farquhar, C. ;
John-Stewart, G. ;
Kakia, A. ;
Odoyo, J. ;
Mucunguzi, A. ;
Nakku-Joloba, E. ;
Twesigye, R. ;
Ngure, K. ;
Apaka, C. ;
Tamooh, H. ;
Gabona, F. ;
Mujugira, A. ;
Panteleeff, D. ;
Thomas, K. K. ;
Kidoguchi, L. ;
Krows, M. ;
Revall, J. ;
Morrison, S. ;
Haugen, H. ;
Emmanuel-Ogier, M. ;
Ondrejcek, L. ;
Coombs, R. W. ;
Frenkel, L. ;
Hendrix, C. ;
Bumpus, N. N. ;
Bangsberg, D. ;
Haberer, J. E. ;
Stevens, W. S. ;
Lingappa, J. R. ;
Celum, C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) :399-410
[7]  
Centers for Disease Control and Prevention, 2020, EST HIV INC PREV US, V25
[8]   Preexposure Prophylaxis for the Prevention of HIV Infection Evidence Report and Systematic Review for the US Preventive Services Task Force [J].
Chou, Roger ;
Evans, Christopher ;
Hoverman, Adam ;
Sun, Christina ;
Dana, Tracy ;
Bougatsos, Christina ;
Grusing, Sara ;
Korthuis, P. Todd .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (22) :2214-2230
[9]   A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine [J].
Cottrell, Mackenzie L. ;
Yang, Kuo H. ;
Prince, Heather M. A. ;
Sykes, Craig ;
White, Nicole ;
Malone, Stephanie ;
Dellon, Evan S. ;
Madanick, Ryan D. ;
Shaheen, Nicholas J. ;
Hudgens, Michael G. ;
Wulff, Jacob ;
Patterson, Kristine B. ;
Nelson, Julie A. E. ;
Kashuba, Angela D. M. .
JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (01) :55-64
[10]   Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017 [J].
Coy, Kelsey C. ;
Hazen, Ronald J. ;
Kirkham, Heather S. ;
Delpino, Ambrose ;
Siegler, Aaron J. .
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2019, 22 (02)